Total Payments
$123,820
2024 Payments
$14,444
Companies
11
Transactions
98
Payment Breakdown by Category
Consulting$76,696 (61.9%)
Travel$42,815 (34.6%)
Food & Beverage$1,863 (1.5%)
Research$1,500 (1.2%)
Other$945.22 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $76,696 | 22 | 61.9% |
| Travel and Lodging | $42,815 | 29 | 34.6% |
| Food and Beverage | $1,863 | 42 | 1.5% |
| Unspecified | $1,500 | 4 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $945.22 | 1 | 0.8% |
Payments by Type
General
$122,320
94 transactions
Research
$1,500
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $35,243 | 15 | $0 (2022) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $20,477 | 13 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $14,433 | 4 | $0 (2018) |
| Janssen Research & Development, LLC | $13,254 | 19 | $0 (2020) |
| Pulmonx Corporation | $7,950 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $7,652 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,533 | 15 | $0 (2023) |
| GlaxoSmithKline, LLC. | $6,301 | 12 | $0 (2018) |
| AstraZeneca UK Limited | $5,292 | 9 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $4,185 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,444 | 15 | AstraZeneca Pharmaceuticals LP ($7,652) |
| 2023 | $38.63 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($38.63) |
| 2022 | $12,185 | 5 | Vertex Pharmaceuticals Incorporated ($8,000) |
| 2021 | $945.22 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($945.22) |
| 2020 | $7,315 | 4 | VERTEX PHARMACEUTICALS INCORPORATED ($3,815) |
| 2019 | $29,078 | 15 | VERTEX PHARMACEUTICALS INCORPORATED ($23,428) |
| 2018 | $35,101 | 34 | Boehringer Ingelheim International GmbH ($14,433) |
| 2017 | $24,713 | 22 | Boehringer Ingelheim Pharma GmbH & Co.KG ($20,477) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,296.00 | General |
| 11/21/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $87.50 | General |
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma • Category: Immunology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $3,356.25 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma • Category: Immunology | ||||||
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $3,578.86 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $1,165.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $127.32 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $127.32 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $76.78 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $58.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $58.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $10.05 | General |
| 09/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma • Category: Immunology | ||||||
| 08/01/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma • Category: Immunology | ||||||
| 08/22/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.59 | General |
| 08/22/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.04 | General |
| 12/15/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Consulting Fee | Cash or cash equivalent | $4,030.00 | General |
| Category: Cardiology | ||||||
| 12/05/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $131.93 | General |
| Category: Cardiology | ||||||
| 12/05/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Cardiology | ||||||
| 10/26/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 01/12/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 07/09/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $945.22 | General |
| Category: RESPIRATORY | ||||||
| 11/23/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $792.00 | General |
| 11/23/2020 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | GENZYME CORPORATION | $1,500 | 4 |
About Dr. George Washko, MD
Dr. George Washko, MD is a Critical Care Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972594752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Washko, MD has received a total of $123,820 in payments from pharmaceutical and medical device companies, with $14,444 received in 2024. These payments were reported across 98 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($76,696).
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Boston, MA
- Active Since 11/02/2005
- Last Updated 09/08/2025
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1972594752
Products in Payments
- STIOLTO RESPIMAT (Drug) $31,385
- Pulmonx Endobronchial Valve EBV (Device) $7,950
- OFEV (Drug) $4,588
- OPSUMIT (Drug) $4,185
- TEZSPIRE (Biological) $3,356
- DUPIXENT (Biological) $1,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Boston
Nicholas Hill, Md, MD
Critical Care Medicine — Payments: $394,549
Critical Care Medicine $394,549
Dr. Joseph Zibrak, Md, MD
Critical Care Medicine — Payments: $167,344
Critical Care Medicine $167,344
Dr. Charles Cote, Md, MD
Critical Care Medicine — Payments: $33,677
Critical Care Medicine $33,677
Lorenzo Berra, Md, MD
Critical Care Medicine — Payments: $31,520
Critical Care Medicine $31,520
Ronald Goldstein, M.d, M.D
Critical Care Medicine — Payments: $12,067
Critical Care Medicine $12,067
Dr. William Gormley, Md, MD
Critical Care Medicine — Payments: $11,878
Critical Care Medicine $11,878